Newsfeeds - Spark Newswire

1 minute read

HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $350

January 20, 7:18 AM

HC Wainwright & Co. analyst Patrick Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $250 to $350.

ALNY

3 minute read

The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week

By Shanthi Rexaline

January 16, 5:38 PM

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference.

ALNY

2 minute read

News

Novartis Announced Three-Year Collaboration With Alnylam to Explore Targeted Therapy to Restore Liver Function

By Charles Gross

January 6, 5:50 AM

Novartis today announced a collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

ALNY

1 minute read

Analyst Ratings

What 9 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

By Benzinga Insights

January 3, 11:11 AM

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

ALNY

1 minute read

Piper Sandler Upgrades Alnylam Pharmaceuticals to Overweight, Raises Price Target to $208

By Benzinga Newsdesk

January 3, 8:22 AM

Piper Sandler analyst Edward Tenthoff upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Neutral to Overweight and raises the price target from $181 to $208.

ALNY

3 minute read

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

By Shanthi Rexaline

December 31, 3:40 PM

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were two new molecular entities.

ALNY

4 minute read

51 Biggest Movers From Yesterday

By Lisa Levin

December 28, 5:23 AM

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.

AERI

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

December 27, 1:38 PM

ALNY

3 minute read

34 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

December 27, 1:01 PM

Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.

ALNY

1 minute read

FDA Approves Alnylam – Novartis’ Leqvio As the First siRNA To Reduce Bad Cholesterol

By Vandana Singh

December 23, 9:20 AM

The

ALNY